Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Finding the cure for primary biliary cholangitis - Still waiting.

Atsushi Tanaka1, M Eric Gershwin2

  • 1Department of Medicine, Teikyo University School of Medicine, Tokyo, Japan.

Liver International : Official Journal of the International Association for the Study of the Liver
|April 4, 2017
PubMed
Summary

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Autophagy of Kupffer cells modulates CD8<sup>+</sup> T cell activation in primary biliary cholangitis.

Gut·2025
Same author

Dietary therapy of murine primary biliary cholangitis induces hepatocellular steatosis: A cautionary tale.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

Conventional type 1 dendritic cells are essential for the development of primary biliary cholangitis.

Liver international : official journal of the International Association for the Study of the Liver·2024
Same author

Targeting pathogenic CD8<sup>+</sup> tissue-resident T cells with chimeric antigen receptor therapy in murine autoimmune cholangitis.

Nature communications·2024
Same author

Immunomodulatory Effects of Microbiota-Derived Short-Chain Fatty Acids in Autoimmune Liver Diseases.

Journal of immunology (Baltimore, Md. : 1950)·2023
Same author

A regulatory variant at 19p13.3 is associated with primary biliary cholangitis risk and ARID3A expression.

Nature communications·2023

Ursodeoxycholic acid (UDCA) helps primary biliary cholangitis (PBC) patients, but many are unresponsive. Obeticholic acid (OCA) offers an alternative, yet lacks critical endpoint data, necessitating further research for personalized PBC treatment.

Area of Science:

  • Hepatology
  • Immunology

Background:

  • Primary biliary cholangitis (PBC) is a chronic liver disease with limited treatment options.
  • Ursodeoxycholic acid (UDCA) is a first-line therapy, but approximately 40% of patients show inadequate response.
  • Earlier diagnosis and epidemiological shifts complicate UDCA efficacy assessment.

Purpose of the Study:

  • To evaluate obeticholic acid (OCA) as an alternative therapy for UDCA-refractory PBC patients.
  • To highlight the need for critical outcome data beyond surrogate markers in PBC clinical trials.
  • To emphasize the necessity of personalized treatment strategies based on individual PBC patient characteristics and biomarkers.

Main Methods:

  • Review of existing clinical trial data for UDCA and OCA in PBC treatment.
  • Discussion of the limitations of surrogate endpoints (e.g., liver histology, immunohistochemistry) versus critical endpoints (e.g., death, liver transplantation).
Keywords:
biological therapyprimary biliary cholangitistolerance

Related Experiment Videos

  • Exploration of the need for novel biomarkers to predict PBC progression and guide individualized therapy.

    • Main Results:

    • While OCA provides an alternative for UDCA-nonresponders, its clinical trial data relies on surrogate endpoints, not definitive outcomes.
    • Current data does not fully capture OCA's impact on critical clinical endpoints like liver transplantation or mortality.
    • Significant heterogeneity in PBC presentation and progression necessitates advanced biomarker identification.

    Conclusions:

    • Further research is crucial to establish OCA's efficacy using critical endpoints in PBC.
    • Development of predictive biomarkers is essential for tailoring PBC therapies to individual patient needs and disease stages.
    • Understanding PBC etiology and achieving a cure remain paramount goals for the scientific community.